Myriad Genetics unveils strong Q4 results and three major diagnostic tests for 2026
Myriad Genetics unveils strong Q4 results and three major diagnostic tests for 2026
Myriad Genetics unveils strong Q4 results and three major diagnostic tests for 2026
Myriad Genetics has released its financial results for the fourth quarter of 2025. The company reported steady revenue growth and highlighted progress in key testing areas. Three major new tests are also set to launch in 2026.
The company's revenue for the fourth quarter of 2025 reached $209.8 million, a 4% increase from the same period in 2024. Without an $8.1 million headwind, the growth would have been stronger. For the full year, revenue totalled $824.5 million, a 2% decline year-over-year but a 2% rise when excluding headwinds.
Gross margin remained stable at 70.0%, matching the previous quarter. The GAAP net loss for Q4 was $7.9 million, or $0.08 per share, while adjusted earnings per share stood at $0.04. Adjusted EBITDA came in at $14.3 million.
Test volumes drove much of the growth, with Prolaris prostate cancer testing up 12% year-over-year. Hereditary cancer testing and GeneSight each saw a 9% increase. The company also noted positive momentum in these areas as 2025 ended.
Looking ahead, Myriad Genetics plans three key launches in 2026. The Precise MRD test, debuting in March, will help detect minimal residual disease in breast cancer patients. Later in the year, it will expand to colorectal and kidney cancer. An AI-enhanced version of the Prolaris prostate cancer test and a new prenatal screen, FirstGene, are also on track. The company expects prenatal testing growth to pick up speed in the coming quarters.
Myriad Genetics closed 2025 with stable financial performance and growth in core testing areas. The upcoming launches of Precise MRD, FirstGene, and the AI-powered Prolaris test mark 2026 as a pivotal year. These developments aim to strengthen the company's position in cancer and prenatal diagnostics.